Interestingly, the treatment with metformin and pioglitazone, two compounds used for the management of metabolic syndrome, has been shown to increase the adiponectin/leptin ratio and improve the inflammatory profile, coinciding with decreased brain lesions in MS patients [51] and reduced cancer risk [52]. This evidence concerns the gene LEP and myeloid sarcoma.